Maximizing Lipophilic Efficiency: The Use of Free-Wilson Analysis in the Design of Inhibitors of Acetyl-CoA Carboxylase
- 11 January 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (2) , 935-942
Abstract
This paper describes the design and synthesis of a novel series of dual inhibitors of acetyl-CoA carboxylase 1 and 2 (ACC1 and ACC2). Key findings include the discovery of an initial lead that was modestly potent and subsequent medicinal chemistry optimization with a focus on lipophilic efficiency (LipE) to balance overall druglike properties. Free-Wilson methodology provided a clear breakdown of the contributions of specific structural elements to the overall LipE, a rationale for prioritization of virtual compounds for synthesis, and a highly successful prediction of the LipE of the resulting analogues. Further preclinical assays, including in vivo malonyl-CoA reduction in both rat liver (ACC1) and rat muscle (ACC2), identified an advanced analogue that progressed to regulatory toxicity studies.Keywords
This publication has 17 references indexed in Scilit:
- Design and synthesis of disubstituted (4-piperidinyl)-piperazine derivatives as potent acetyl-CoA carboxylase inhibitorsBioorganic & Medicinal Chemistry Letters, 2010
- (4-Piperidinyl)-piperazine: A new platform for acetyl-CoA carboxylase inhibitorsBioorganic & Medicinal Chemistry Letters, 2009
- Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007 – 2008Expert Opinion on Therapeutic Patents, 2009
- Synthesis of spiro[chroman-2,4′-piperidin]-4-one derivatives as acetyl-CoA carboxylase inhibitorsBioorganic & Medicinal Chemistry Letters, 2009
- Inhibitors of Mammalian Acetyl-CoA CarboxylaseRecent Patents on Cardiovascular Drug Discovery, 2007
- Disordered Lipid Metabolism and the Pathogenesis of Insulin ResistancePhysiological Reviews, 2007
- Increased Malonyl-CoA Levels in Muscle From Obese and Type 2 Diabetic Subjects Lead to Decreased Fatty Acid Oxidation and Increased Lipogenesis; Thiazolidinedione Treatment Reverses These DefectsDiabetes, 2006
- Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2Journal of Clinical Investigation, 2006
- Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk Factors, 2001JAMA, 2003
- Cellular mechanisms of insulin resistanceJournal of Clinical Investigation, 2000